[
    [
        {
            "time": "2023-10-01",
            "original_text": "白雲山：分拆廣州醫藥赴港上市，融資、業務與估值一箭多雕",
            "features": {
                "keywords": [
                    "白雲山",
                    "分拆",
                    "廣州醫藥",
                    "赴港上市",
                    "融資",
                    "業務",
                    "估值"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "醫療",
                    "製藥"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "白雲山：分拆廣州醫藥赴港上市，融資、業務與估值一箭多雕",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-02",
            "original_text": "白雲山：融資業務與估值一箭多雕 增持評級",
            "features": {
                "keywords": [
                    "白雲山",
                    "融資",
                    "業務",
                    "估值",
                    "增持評級"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "醫療",
                    "製藥"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "白雲山：融資業務與估值一箭多雕 增持評級",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-03",
            "original_text": "港股異動 | 白雲山漲逾3% 擬準備子公司廣州醫藥赴港上市",
            "features": {
                "keywords": [
                    "白雲山",
                    "港股",
                    "異動",
                    "漲逾3%",
                    "廣州醫藥",
                    "赴港上市"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "醫療",
                    "製藥"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股異動 | 白雲山漲逾3% 擬準備子公司廣州醫藥赴港上市",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-04",
            "original_text": "白雲山(00874-HK)擬出售應收賬款資產的交易 資產異常",
            "features": {
                "keywords": [
                    "白雲山",
                    "應收賬款",
                    "資產異常",
                    "出售"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "醫療",
                    "製藥"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "白雲山(00874-HK)擬出售應收賬款資產的交易 資產異常",
                "Correlation": 8,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "白雲山(00874-HK)建議分拆廣州醫藥聯交所上市",
            "features": {
                "keywords": [
                    "白雲山",
                    "分拆",
                    "廣州醫藥",
                    "聯交所上市"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "醫療",
                    "製藥"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "白雲山(00874-HK)建議分拆廣州醫藥聯交所上市",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]